North York General Hospital

The trials here

What the 15 trials at this site are about, from their registry records.

Conditions

• Huntington's disease5 trials
• Colorectal cancer2 trials
• Metastatic breast cancer2 trials
• Bladder cancer1 trial
• Down syndrome1 trial
• Lung cancer1 trial
• Obesity1 trial
• Osteoarthritis1 trial
• Ovarian cancer1 trial

Phase

• Phase 35 trials
• Phase 2/33 trials
• Phase 22 trials

Status

• Active, not recruiting5 trials
• Recruiting5 trials
• Completed3 trials
• Not yet recruiting1 trial
• Terminated1 trial

Lead sponsor

• Hoffmann-La Roche4 trials
• Canadian Cancer Trials Group2 trials
• NRG Oncology2 trials
• Alliance for Clinical Trials in Oncology1 trial
• CHDI Foundation, Inc.1 trial
• and 5 more

Running trials

• Recruiting

  Pridopidine Phase 3 Study in Huntington's Disease

  NCT07609108· Phase 3· Prilenia· Source

• Recruiting

  Study to Evaluate the Pharmacodynamics, Safety and Efficacy of SKY-0515 in Participants With Huntington's Disease

  NCT07378644· Phase 2/3· Skyhawk Therapeutics, Inc.· Source

  Contact: Clare Gibbons

• Active, not recruiting

  A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)

  NCT06065748· Phase 3· Hoffmann-La Roche· Source

• Recruiting

  Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease

  NCT05174169· Phase 2/3· NRG Oncology· Source

  Contact: Kathryn A. Towns (principal investigator)

• Active, not recruiting

  Circulating Tumor DNA Testing in Predicting Treatment for Patients With Stage IIA Colon Cancer After Surgery

  NCT04068103· Phase 2/3· NRG Oncology· Source

• Active, not recruiting

  ASA in Prevention of Ovarian Cancer (STICs and STONEs)

  NCT03480776· Phase 2· Canadian Cancer Trials Group· Source

• Active, not recruiting

  Durvalumab and Tremelimumab ± Platinum-Based Chemotherapy in Patients With Metastatic Squamous or Non-Squamous NSCLC

  NCT03057106· Phase 2· Canadian Cancer Trials Group· Source

• Recruiting

  HDClarity: a Multi-site Cerebrospinal Fluid Collection Initiative to Facilitate Therapeutic Development for Huntington's Disease

  NCT02855476· University College, London· Source

  Contact: Rebecca Searles

• Active, not recruiting

  Breast Cancer WEight Loss Study (BWEL Study)

  NCT02750826· Phase 3· Alliance for Clinical Trials in Oncology· Source

• Recruiting

  Enroll -HD: A Prospective Registry Study in a Global Huntington's Disease Cohort

  NCT01574053· CHDI Foundation, Inc.· Source

  Contact: Clare Gibbons

• Recruiting

  Specimen Collection From Pregnant Women at Increased Risk for Fetal Aneuploidy

  NCT01429389· Sequenom, Inc.· Source

  Contact: Clare Gibbons

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Huntington's disease4 recruiting
• Colorectal cancer1 recruiting
• Down syndrome1 recruiting

Closed trials

• Completed

  Frequency of Selected Single Nucleotide Polymorphisms in Huntington Disease Gene Expansion Carriers

  NCT06667414· Hoffmann-La Roche· Source

• Completed

  A Study to Evaluate Patient Preference for Home Administration of Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Administration in Participants With Early or Locally Advanced/Inflammatory HER2-Positive Breast Cancer

  NCT05415215· Phase 3· Hoffmann-La Roche· Source

• Terminated

  Function, Pain, and Alignment Following Knee Replacement for the Treatment of Osteoarthritis

  NCT05490186· North York General Hospital· Source

• Completed

  Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma

  NCT02807636· Phase 3· Hoffmann-La Roche· Source